San Francisco, United States
ZBiotics, founded in 2016 by Zack Abbott, a PhD microbiologist, is gaining attention in the Biotechnology and Food and Beverage industries. The company's foremost achievement is being the maker of the world's 1st genetically engineered probiotic, aimed at enhancing daily life.
Their initial offering is a breakthrough probiotic designed to mitigate the after-effects of alcohol consumption, providing a novel solution for improved next-day wellness. This product exemplifies the company's underlying principle of employing genetic engineering that prioritizes transparency, responsibility, and a people-first approach.
ZBiotics, headquartered in the United States, recently secured a $22.42M Series A investment, with backing from Seaside Ventures as of 26 March 2024. This capital infusion is poised to advance their innovative pipeline, introducing new genetically engineered products that address various modern life's challenges. This positions ZBiotics as a transformative player potentially redefining product experiences across diverse markets.
